New combo therapy targets advanced cancers in early trial
Disease control
Ongoing
This study tests a new drug called Q702 combined with pembrolizumab (a standard immunotherapy) in people with advanced esophageal, stomach, liver, or cervical cancer that has worsened after prior treatment. The goal is to see if the combination is safe and can shrink tumors or sl…
Phase: PHASE1, PHASE2 • Sponsor: Qurient Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 04:15 UTC